BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > IT > article

S. Korea ready for clinical trial of immunoglobulin drug based on plasma containing antibodies

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : August 11, 2020, 18:02 | Updated : August 11, 2020, 18:02
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Inha University]

SEOUL -- South Korea is ready to conduct the clinical trial of an immunoglobulin drug based on plasma containing antibodies in hospitals to treat COVID-19 patients. In five hospitals, 60 people will be given drugs to set proper dosage and check safety and efficacy.

The Korea Centers for Disease Control and Prevention (KCDC) has unveiled a roadmap for the treatment of COVID-19 to develop plasma treatment by the year's end as well as antibody treatment and vaccines next year. GC Pharma, a biotech company, is working with the state-run National Institutes of Health to develop plasma treatment by collecting blood from 642 people.

"The manufacturing process for the clinical trial of plasma therapy was completed on August 10," KCDC Deputy Director Kwon Jun-wook said in a regular press briefing. "If approved, we will immediately start clinical testing on patients."

Plasma treatment is different from plasma therapy which involves the infusions of blood plasma from COVID-19 survivors to patients. South Korean drug and bio companies have jumped into the race to develop vaccines or treatments, while doctors have formed a task force to find proper treatment by mixing antiviral drugs.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Antiviral drug remdesivir available in S. Korea to treat COVID-19 patients .
    Antiviral drug remdesivir available in S. Korea to treat COV…
  • .Jeong Eun-kyeong promoted to head S. Koreas new disease control tower.
    Jeong Eun-kyeong promoted to head S. Korea's new disease con…
  • .S. Korea uses digital payment more frequently to offer condolence money amid pandemic.
    S. Korea uses digital payment more frequently to offer condo…

Real Time Photo News

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

  • .​Solo singer Sunmi to come back with new album Tail.

    ​Solo singer Sunmi to come back with new album 'Tail'

  • .Big Hits live-streaming joint venture gains reinforcements from Universal Music, YG.

    Big Hit's live-streaming joint venture gains reinforcements from Universal Music, YG

Latest News

more+

  • Prime Minister Chung stresses importance of 'borderless communication channel' to minimize informati…
  • State hospital succeeds in inserting wireless pacemakers into hearts of bradyarrhythmia patients
  • LG Electronics' joint venture with Canada's Magna awaits approval by shareholders in March
  • Sajo Seafood to launch raw tuna menu delivery service
  • Researchers find new roundworm species near Dokdo
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view